Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer

被引：0
|
作者：
Rustin, G. J.
Reed, N. S.
Jayson, G.
Ledermann, J. A.
Adams, M.
Stredder, C.
Wagner, A.
Giurescu, M.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] Christie Hosp, Manchester, Lancs, England
[4] UCL, London, England
[5] Velindre Hosp, Cardiff, S Glam, Wales
[6] Schering Hlth Care Ltd, Burgess Hill, W Sussex, England
[7] Bayer Schering Pharma AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5527
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer
    Rustin, G.
    Reed, N.
    Jayson, G. C.
    Ledermann, J. A.
    Adams, M.
    Perren, T.
    Poole, C.
    Lind, M.
    Persic, M.
    Essapen, S.
    Gore, M.
    Calvert, H.
    Stredder, C.
    Wagner, A.
    Giurescu, M.
    Kaye, S.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2411 - 2416
  • [2] Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma
    Wenk, D.
    DeConti, R. C.
    Urbas, P.
    Andrews, S.
    Sondak, V. K.
    Maker, N.
    Weber, J. S.
    Daud, A. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Phase II Study of the Novel Epothilone Sagopilone (ZK-EPO) in Patients with Progressive Metastatic Breast Cancer.
    Campone, M.
    Dittrich, C.
    Cufer, T.
    Dudov, A.
    Phan, Dao P.
    Schmelter, T.
    Giurescu, M.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 858S - 859S
  • [4] Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma
    Daud, A.
    Weber, J.
    Urbas, P.
    Andrews, S.
    Maker, N.
    Sondak, V. K.
    DeConti, R. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Significant antiturnour activity of the novel epothilone ZK-EPO against in vitro and in vivo models of ovarian cancer
    Hammer, S.
    Arnold, N.
    Hilpert, F.
    Braeutigam, K.
    Sommer, A.
    Winsel, S.
    Klar, U.
    Hoffmann, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 313 - 314
  • [6] Subcellular distribution and cellular activity of the novel epothilone ZK-EPO
    Winsel, S.
    Hammer, S.
    Eschenbrenner, J.
    Mittelstaedt, K.
    Buchmann, B.
    Schwede, W.
    Skuballa, W.
    Klar, U.
    Hoffmann, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 113 - 113
  • [7] Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
    Schmid, P.
    Kiewe, P.
    Possinger, K.
    Korfel, A.
    Lindemann, S.
    Giurescu, M.
    Reif, S.
    Wiesinger, H.
    Thiel, E.
    Kuehnhardt, D.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 633 - 639
  • [8] Weekly administration of ZK-EPO, a novel third-generation epothilone, in patients with refractory solid tumors: Results of a phase I trial
    Arnold, Dirk
    Voigt, Wieland
    Kiewe, Philipp
    Behrmann, Curd
    Lindemann, Stefanie
    Reif, Stefanie
    Giurescu, Marius
    Thiel, Eckhard
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [9] A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors.
    Schmid, P
    Kiewe, P
    Kuehnhardt, D
    Korfel, A
    Lindemann, S
    Giurescu, M
    Reif, S
    Thiel, E
    Possinger, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 147S - 147S
  • [10] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J., II
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    Schmelter, T.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 70 - 76
12345